ReviewPharmaceutics2021
Ruthenium Complexes in the Fight against Pathogenic Microorganisms. An Extensive Review.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 87 citations in OpenAlex.
- Metal coordination at biological interfaces: Mechanisms, therapeutics, and translation.Materials today. Bio · 2026Review
- Enhancing the Antimicrobial Photodynamic Activity of Heteroleptic Ruthenium(II) Complexes: Role of AsymmetricInorganic chemistry · 2026Article
- Activity Against ESKAPE Bacterial Pathogens of Pyrazole-Indol-Ruthenium(II) Complexes.Antibiotics (Basel, Switzerland) · 2026Article
- Spectroscopic characterization and geometry optimization of a ruthenium(II) complex with a limonene-derived amino-oxime ligand: DFT/TD-DFT inspection, in silico molecular docking, and dynamics simulations for a potent cancer drug.Journal of computer-aided molecular design · 2026Article
- Organic Materials for Biohybrid Photocatalysis and Photoelectrochemical Devices.Chemical reviews · 2026Review
- Coordination chemistry-enabled drug delivery systems: metal-ligand platforms for controlled release and targeted therapeutics.Journal of nanobiotechnology · 2026Review
- Design and synthesis of bioactive Ru(ii) complexes: antibacterial activity, biocompatibility and biomolecular binding.RSC advances · 2025Article
- Structural and biomedical investigations of novel ruthenium schiff base complexes.Scientific reports · 2025Article
- Transition metal complexes: next-generation photosensitizers for combating Gram-positive bacteria.Future medicinal chemistry · 2025Review
- Chloride and Acetonitrile Ruthenium(IV) Complexes: Crystal Architecture, Chemical Characterization, Antibiofilm Activity, and Bioavailability in Biological Systems.Molecules (Basel, Switzerland) · 2025Article
- Ruthenium Complexes with Pyridazine Carboxylic Acid: Synthesis, Characterization, and Anti-Biofilm Activity.Molecules (Basel, Switzerland) · 2024Article
- Platinum Group Metals Nanoparticles in Breast Cancer Therapy.Pharmaceutics · 2024Review
- Advances in Cholinesterase Inhibitor Research-An Overview of Preclinical Studies of Selected Organoruthenium(II) Complexes.International journal of molecular sciences · 2024Review
- Ruthenium(II) Complex-Based Tetradentate Schiff Bases: Synthesis, Spectroscopic, Antioxidant, and Antibacterial Investigations.International journal of molecular sciences · 2024Article
- Engineering of bespoke photosensitiser-microbe interfaces for enhanced semi-artificial photosynthesis.Chemical science · 2024Review
- Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Impact of mucus and biofilm on antimicrobial photodynamic therapy: Evaluation using Ruthenium(II) complexes.Biofilm · 2023Article
- Photodynamic Eradication ofPharmaceutics · 2023Article
- Transition metals in angiogenesis - A narrative review.Materials today. Bio · 2023Review
- Silica-Based Materials Containing Inorganic Red/NIR Emitters and Their Application in Biomedicine.Materials (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The widespread use of antibiotics has resulted in the emergence of drug-resistant populations of microorganisms. Clearly, one can see the need to develop new, more effective, antimicrobial agents that go beyond the explored 'chemical space'. In this regard, their unique modes of action (e.g., reactive oxygen species (ROS) generation, redox activation, ligand exchange, depletion of substrates involved in vital cellular processes) render metal complexes as promising drug candidates. Several Ru (II/III) complexes have been included in, or are currently undergoing, clinical trials as anticancer agents. Based on the in-depth knowledge of their chemical properties and biological behavior, the interest in developing new ruthenium compounds as antibiotic, antifungal, antiparasitic, or antiviral drugs has risen. This review will discuss the advantages and disadvantages of Ru (II/III) frameworks as antimicrobial agents. Some aspects regarding the relationship between their chemical structure and mechanism of action, cellular localization, and/or metabolism of the ruthenium complexes in bacterial and eukaryotic cells are discussed as well. Regarding the antiviral activity, in light of current events related to the Covid-19 pandemic, the Ru (II/III) compounds used against SARS-CoV-2 (e.g., BOLD-100) are also reviewed herein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.